Immunovia Publishes Interim Report for January-June 2023
April-June 2023 · Net sales amounted to kSEK 412 (103) divided by sales of tests kSEK 351 (45) and royalties kSEK 61 (58). · Net earnings were MSEK -170 (-34) and earnings per share before and after dilution were SEK -4.00 (-1.49). · Earnings during the second quarter has been charged with SEK 141 million, which mainly consist of non-cash flow one-off costs such as depreciation and write-downs of intangible assets as a result of the decision to cease commercialization of the IMMray™ PanCan-d test in the US, but also termination and severance pay which will have a cash impact. ·